Compare Fox Corp Class B (FOX) vs Hims and Hers Health Inc (HIMS) Price & Performance

FOX trades at $49.50, down 1.43% today, with technical indicators showing a neutral to bearish short-term bias. The company demonstrates strong fundamental performance with Q1 2026 EPS beating expectations at $1.32 versus $0.988, continuing a trend of earnings surprises. Revenue grew to $16.3B in 2025 with net income margin expanding to 13.88%. Analyst sentiment is mixed with 43% buy ratings but technical weakness persists near key support levels.

The outlook remains cautiously optimistic given FOX's consistent earnings beats and improved cash flow generation, though technical weakness and competitive pressures in media streaming present near-term challenges. The stock offers reasonable valuation with P/E of 13.26x, but investors should monitor advertising trends and Roku integration execution risks.

Hims & Hers Health trades at $35.52, up 1.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $33.57. Recent earnings show volatility with a Q1 2026 miss, but revenue grew to $2.35 billion in 2025. The company benefits from expansion in weight-loss therapies and a $400 million JPMorgan facility, though high valuations like a P/E of 57.14 and negative net income margin pose concerns.

Outlook is mixed: growth opportunities in telehealth and GLP-1 drugs support upside, but earnings inconsistency and regulatory risks from FDA reviews require caution. Analysts are 35% buy-rated, highlighting potential if execution improves, yet investors face volatility near key resistance at $38.